Quick Facts

• Main Uses: May help manage erectile dysfunction in adult males.
• Secondary Use: Used to assist in the management of pulmonary arterial hypertension (PAH).
• Goal: May help to improve physical ability in individuals with PAH.

Sildenafil is a therapeutic option utilized for the management of two primary conditions, based on its established effects on blood flow regulation.

The medication is approved to help adult males who experience erectile dysfunction. In this context, it may assist with the ability to get and keep an erection when sexual stimulation is present. It is important to note that this treatment does not address the underlying cause of the condition.

Additionally, Sildenafil is used to manage pulmonary arterial hypertension (PAH), a type of high blood pressure affecting the vessels that carry blood to the lungs. For individuals with PAH, the medication may help to improve exercise ability and may contribute to a reduction in the rate of clinical worsening of the condition. Treatment for PAH using this agent has been evaluated in clinical studies to improve exercise tolerance.

It is essential to consult with a qualified healthcare professional to determine if this treatment is appropriate for a specific condition.

Regulatory References

1. NIH MedlinePlus guidance on Sildenafil

Official Eligibility Rules for Sildenafil Use

Regulatory documents define strict population eligibility for Sildenafil, which is the active ingredient in Sildenafil Helvepharm, based on contraindications, age, and existing health conditions.

Populations for Whom Use is Contraindicated

Use of this medicine is strictly prohibited (contraindicated) for patients receiving any form of organic nitrates or nitric oxide donors, or guanylate cyclase stimulators (e.g., riociguat). It must also not be used by patients with a history of severe hypotension (resting BP < 90/50 mmHg), severe hepatic impairment, or a recent history of stroke or myocardial infarction. Individuals who have experienced non-arteritic anterior ischaemic optic neuropathy (NAION) are also ineligible.

Eligibility Based on Age and Condition

• Adults: Eligible for both the erectile dysfunction (ED) and pulmonary arterial hypertension (PAH) indications. For older adults (65 years and over), caution is noted due to reduced clearance.
• Pediatric Patients: Approved for PAH in children aged 1 year and older, but use is not established for infants under one year.
• Restricted Use: The medicine is used with caution in patients with severe renal impairment, hepatic impairment, or conditions predisposing to priapism (e.g., sickle cell disease). Eligibility is also restricted in men for whom sexual activity is inadvisable due to severe cardiovascular issues.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Sildenafil Helvepharm based on clinically significant drug-drug and product interactions.

Contraindicated Combinations

Sildenafil is strictly contraindicated for use with any form of Nitric Oxide Donors or Organic Nitrates (e.g., Nitroglycerin, Isosorbide Mononitrate) due to the risk of severe, life-threatening hypotension resulting from potentiation of the cGMP pathway. The use with Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat) is also contraindicated for the same reason.

Pharmacokinetic Interactions

Sildenafil is principally cleared from the body via the CYP3A4 enzyme system. Co-administration with strong CYP3A4 inhibitors (e.g., Ritonavir, Ketoconazole, Erythromycin) can substantially increase the plasma concentration and exposure of Sildenafil. This requires specific dose restrictions, such as limiting the maximum dose and frequency when used with potent inhibitors. Conversely, strong CYP3A4 inducers (e.g., Rifampin, St. John’s Wort) may decrease Sildenafil concentration and efficacy.

Pharmacodynamic and Other Interactions

Caution is advised when Sildenafil is co-administered with alpha-blockers or other antihypertensive agents due to the potential for additive blood pressure lowering effects, which may lead to symptomatic hypotension, most likely occurring within four hours of dosing. The safety of using Sildenafil concurrently with other PDE5 inhibitors has not been studied, and co-administration is not recommended. Grapefruit juice may also modestly increase plasma levels of Sildenafil.

Selective Inhibition of the PDE5 Enzyme

The primary action of Sildenafil is to function as a selective competitive inhibitor of the enzyme cGMP-specific phosphodiesterase type 5 (PDE5). This enzyme typically breaks down the signaling molecule cyclic Guanosine Monophosphate (cGMP) in smooth muscle cells. By blocking this enzyme, Sildenafil results in the molecular accumulation of cGMP.

---

Potentiation of the NO / cGMP Signaling Cascade

The accumulation of cGMP potentiates the signaling cascade initiated by endogenous Nitric Oxide (NO). This action activates downstream enzymes, which ultimately causes the relaxation of vascular smooth muscle cells and subsequent vasodilation (blood vessel widening). Critically, this mechanism is strictly dependent on the initial release of NO by the body, meaning the drug acts only as a potentiator, not an initiator, of the physiological response.

---

Resulting Localized Physiological Adjustment

The sequence of PDE5 inhibition and cGMP potentiation produces the physiological effect of localized blood flow modulation in specific vascular beds where the PDE5 enzyme is prevalent. This physiological event results from the modulation of vascular smooth muscle tone.

How to Use Sildenafil Helvepharm

Sildenafil Helvepharm is administered orally in the form of film-coated tablets and is prescribed for intermittent, as-needed use, not a continuous daily regimen. The use protocol involves specific parameters concerning dosage, timing, and patient-specific considerations.

---

Official Administration Guidelines

Instruction Entity	General Specification
Route of Administration	Oral (swallowed whole with liquid).
Standard Dosing Range	25 mg to 100 mg as a single dose.
Maximum Single Dose	100 mg.
Dosing Frequency	Maximum of once per day (once every 24 hours).
Timing Relative to Activity	Taken approximately one hour before activity; may be taken 30 minutes to 4 hours prior.
Food Effect	Taking with a high-fat meal may delay the onset of activity.

---

Population-Specific Adjustments

Official labeling specifies dose considerations for patients with impaired clearance of the medicine. A starting dose of 25 mg should be considered for individuals diagnosed with severe renal impairment (creatinine clearance <30 mL/min), those with hepatic impairment, or certain older adults (65 years in some regions).

Administration Constraint

Procedural constraints apply when the medicine is co-administered with specific interacting compounds. For instance, the maximum dose must be limited to 25 mg within a 48-hour period if co-administered with ritonavir. This ensures adherence to established pharmacokinetic limits.

Research evidence / Overview of Studies for Sildenafil Helvepharm

Evidence for use in Erectile Dysfunction (ED)

Research examining the use of Sildenafil for adult males with erectile dysfunction (ED) was evaluated in clinical trials, relying primarily on well-designed short-term, randomized controlled trials (RCTs). These studies were often double-blind and compared Sildenafil to placebo, which is a common study design used to measure responses. The trials were designed to observe responses over defined time intervals.

Studies examined outcomes related to physical discomfort and sexual activity measures. This included objective measurements of penile rigidity and duration, as well as patient-reported outcomes describing erection characteristics. Research so far indicates that studies described patterns in the measured outcomes relevant to erection measures. Findings describe patterns observed in the studies related to patient-reported outcomes among the observed populations.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

Sildenafil was evaluated in multinational, multicenter, randomized, and placebo-controlled trials for individuals with pulmonary arterial hypertension (PAH). Research examined outcomes related to systemic or functional imbalance.

Studies monitored physiological strain and outcomes related to daily functioning. Studies monitored functional exercise capacity, such as the six-minute walk distance (6MWD). Additionally, research monitored outcomes describing episodic or acute changes, specifically examining findings related to clinical worsening or disease progression. Findings describe patterns observed in the studies related to measured outcomes, and trials reported how outcomes evolved in the observed populations across the measured timeframes.

Long-term Studies and Durability of Response

For both indications, the initial pivotal trials were typically conducted over short-term periods, generally lasting 12 to 16 weeks. These short-term studies provided the primary insight into changes measured during the study period.

For PAH, research was continued in long-term open-label extension studies where all participants received the active compound. These extended studies contribute to the broader evidence landscape by providing context regarding the duration of evidence. However, because these extension studies do not have a simultaneous control group, the evidence for long-term outcomes is not fully established with the same degree of certainty as the initial short-term RCTs.

Research in Specific Patient Groups

Sildenafil was studied for adult males with ED where the condition was linked to specific health issues. Research explored short-term symptom changes in populations with ED associated with diabetes and those with spinal cord injury. While studies described how outcomes evolved in the observed populations, findings were mixed for certain groups, with some trials describing patterns that differed when compared to the general ED population. Research provides context but not individual predictions, and study findings apply only to the populations studied.

The use in PAH was also evaluated in dedicated studies involving pediatric patients (aged 1 to 17 years). Research describes these specific populations, but there is limited information for long-term outcomes, which creates an area of uncertainty.

The Overall Strength and Consistency of the Evidence

For both erectile dysfunction and pulmonary arterial hypertension, the research base includes a substantial number of high-quality Randomized Controlled Trials (RCTs) and subsequent systematic reviews. This type of evidence contributes to understanding symptom patterns within the studied populations. Evidence helps contextualize how patients reported their experience and provides insight into short-term changes.

The evidence quality varies across studies, however, particularly when looking at specific subgroups, and the data for certain groups remain limited, especially concerning outcomes related to extended use.

Key Research Gaps and Uncertainties

Despite the existence of a high volume of short-term RCTs, certain aspects of the medicine's profile remain uncertain. Long-term effects are not fully established with the high certainty afforded by long-term controlled trials, as follow-up durations were limited in the initial efficacy studies.

Furthermore, findings were mixed regarding the long-term use in pediatric PAH patients. Studies examining temporary physiological imbalance in this group was observed in some studies with specific findings that contributed to uncertainty regarding long-term use in children. Data for certain groups remain insufficient, and the evidence highlights what is known—and what is still uncertain—about long-term outcomes.

Common questions about Sildenafil Helvepharm (FAQ)

---

Q: Can Sildenafil Helvepharm interact negatively with alcohol consumption?

A: Official product information notes that consuming excessive amounts of alcohol may not be appropriate when using this medicine. Drinking too much alcohol is noted as potentially hindering the intended physiological response of the medicine. Alcohol may also contribute to the occurrence of certain documented side effects, such as dizziness.

Q: Are there any common foods or supplements that should be avoided when using Sildenafil Helvepharm?

A: Regulatory information indicates that consuming grapefruit juice may cause modestly increased levels of Sildenafil in the body. Taking the tablet with a high-fat meal is also noted to potentially delay how quickly the medicine starts to work. Furthermore, certain strong enzyme-inducing supplements, such as St. John's wort, are mentioned as they may decrease the concentration of Sildenafil.

Q: Is it safe to drive or operate machinery after taking Sildenafil Helvepharm?

A: Due to the potential for side effects like dizziness and vision changes, official documents advise patients to know how they react to the medicine. If these effects occur, official safety information suggests avoiding activities such as driving or operating machinery.

Q: Is it possible for Sildenafil Helvepharm to lose its effectiveness over time?

A: Research from clinical trials, including long-term extension studies, does not establish a definitive finding of drug tolerance or a clear loss of effectiveness over time in the studied populations. These studies were designed to evaluate the duration of the measured response.

Q: What should be stored in the package leaflet for Sildenafil Helvepharm?

A: The official Package Leaflet (or Patient Information Leaflet) is required to contain key information about the medicine. This includes instructions for correct use, a list of known side effects, specific warnings, proper storage conditions, and a list of all active and inactive ingredients.

Q: Is Sildenafil Helvepharm safe for people who have heart conditions?

A: Use is strictly restricted for individuals who have recently experienced a stroke or heart attack, or who have specific, severe forms of low blood pressure. Use is restricted for individuals with severe heart conditions, and official information emphasizes careful consideration by a health professional for any patient with underlying cardiovascular issues.

Q: Do women ever use Sildenafil Helvepharm, and if so, for what purpose?

A: Sildenafil is officially indicated for the treatment of Pulmonary Arterial Hypertension (PAH) in adult women. However, official regulatory documents specify that Sildenafil is not indicated for the treatment of erectile dysfunction in women.

Q: Are there different strengths or dosages of Sildenafil Helvepharm available?

A: Sildenafil is commonly manufactured as film-coated tablets in various strengths which align with the different available dose sizes. The specific strengths available depend on the brand and country of authorization.

Q: Does Sildenafil Helvepharm affect fertility or sperm count?

A: Official non-clinical and clinical data on healthy men indicates that a single maximum dose did not have an observed effect on sperm motility (the ability of sperm to move) or the structure of the sperm.

Q: How does the body get rid of Sildenafil Helvepharm after it's been taken?

A: The body primarily removes Sildenafil by breaking it down in the liver. This process is carried out by specific enzyme systems, mainly the cytochrome P450 CYP3A4 enzyme, before the medicine is then eliminated from the body.

Q: What are the most common reasons people stop using Sildenafil Helvepharm?

A: In clinical trials, the primary reasons reported for participants stopping use of the medicine were typically related to the occurrence of adverse events. These events were most often associated with the commonly known side effects of the drug.

Q: Is Sildenafil Helvepharm available in a form other than a tablet?

A: While Sildenafil Helvepharm is presented as film-coated tablets for oral use, the active ingredient, Sildenafil, is also available in an injectable form and as an oral suspension for treating specific indications like Pulmonary Arterial Hypertension.

Q: Does the effectiveness of Sildenafil Helvepharm change with age?

A: Regulatory documents recommend dose adjustments for older adults, generally those 65 years and over, because the medicine is cleared from the body more slowly with age. However, official information does not specify that the core measure of effectiveness is inherently changed due to age alone.

Q: Can Sildenafil Helvepharm be used by people with diabetes?

A: Sildenafil was studied in men with erectile dysfunction associated with diabetes mellitus. While studies were conducted and results were described, official labeling does not include a contraindication specifically based on a diabetes diagnosis.

Q: Is it true that Sildenafil Helvepharm only works if a person is sexually stimulated?

A: Yes, official documentation explicitly states that for the medicine to be effective in the treatment of erectile dysfunction, sexual stimulation is required. The drug works by enhancing the body's natural response mechanisms, which must first be activated.

Q: What kind of studies have been done on the long-term effects of Sildenafil Helvepharm?

A: Clinical research included open-label extension studies for specific patient groups, which provided data on safety and observed outcomes over multiple years. However, high-certainty evidence of long-term effects from randomized, controlled trials is noted as limited.

Q: What is the maximum number of times Sildenafil Helvepharm should be taken in one day?

A: The official recommended maximum dosing frequency is strictly limited to once per day (once every 24 hours).

Q: Is there a different name for Sildenafil Helvepharm in other countries?

A: Sildenafil is the name of the active substance, but 'Helvepharm' is a specific brand name authorized in certain regions. The same active ingredient is marketed under various different brand names globally.

Q: Does Sildenafil Helvepharm contain lactose or gluten?

A: Official patient information lists all inactive ingredients, or excipients. Many film-coated tablet formulations of Sildenafil contain lactose as an excipient. If there are concerns about specific ingredients, the package leaflet should be consulted.

Q: Can Sildenafil Helvepharm be crushed or split for easier use?

A: The tablets are intended to be swallowed whole with water. Official regulatory documents state the tablets should be swallowed whole and do not provide instructions for crushing or splitting.

Q: Is Sildenafil Helvepharm only for men with physical causes of erectile dysfunction?

A: The medicine’s mechanism of action requires sexual stimulation to trigger the natural release of nitric oxide in the body. This means the drug works by potentiating a physical response, and its use is not restricted only to those with diagnosed physical causes of the condition.

How to Store and Dispose of Sildenafil Helvepharm

Storage and disposal of Sildenafil Helvepharm must adhere to official regulatory requirements to maintain product stability and safety.

Storage Requirements

Sildenafil film-coated tablets must be stored in their original package and the container must be kept tightly closed in order to protect from moisture. While some labeling states that no special temperature conditions are required, other official labeling specifies that the medicine must not be stored above 30 C.

For child safety, the product must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired Sildenafil Helvepharm must be disposed of in accordance with local requirements. Official guidance restricts throwing the medicine away via wastewater or common household waste. In many regions, unused medicine should be taken to a formal drug take-back location or mixed with an undesirable substance, sealed in a container, and then discarded in household trash.